CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 442 enrolled
Drug / intervention
Peginterferon alfa-2b (SCH 54031) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00724373
NCT00724373N/ACompleted
CompareCT.gov

Retrospective Data Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol

Merck Sharp & Dohme LLC·observational·Posted Jul 29, 2008·Updated Sep 25, 2015

In Brief

An observational study evaluating Peginterferon alfa-2b (SCH 54031) and Ribavirin (SCH 18908) for Hepatitis C, Chronic. Completed, enrolled 442 participants.

Detailed Summary

The study is designed as a retrospective data review of medical records from participants selected from specialist secondary and tertiary care centers across the United Kingdom (UK), specializing in Hepatitis C treatment. The study is non-interventional and is designed to identify subgroups of Hepatitis C Virus (HCV) genotype 1 participants in the 'real world', including the relation between subgroup characteristics and treatment responsiveness.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 29, 2008
Enrollment StartNov 1, 2007
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.9 years ago

Interventions

Peginterferon alfa-2b (SCH 54031)biological

Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.

Ribavirin (SCH 18908)drug

Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.